Clinical trials: Type 2 Diabetes Mellitus 1
Diabetes Mellitus
Post-Market Clinical Follow-Up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in Patients With Type 1 and Type 2 Diabetes Mellitus
Post market Clinical follow-up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in patients with Type 1 and Type 2 Diabetes Mellitus
- Trial name
- NCT07122180
- Testing
- CT3 Series Continuous Glucose Monitoring System:
- Where
- Latvia
- Volunteers
- 72 people
- Sponsor
- MDCECRO LLC
Type 1 Diabetes
Study of Insulin Therapy Augmented by Real Time Sensor IN Type 1 Children and Adolescents (START-IN!)
Glycemic control in children and adolescent with type 1 diabetes remains inadequate, exposing them to the risk of vascular complications in adulthood.
- Trial name
- START-IN (NCT00949221)
- Testing
- monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
The Effect of Viscous Fiber on Glycemic Control in Individuals With Diabetes
Purpose of Study (The Effect of Viscous Fiber on Glycemic Control (VF \& GC) in Individuals with Diabetes Mellitus. According to the World Health Organization, about 347 million individuals are living with diabetes.
- Trial name
- VF&GC (NCT02629263)
- Testing
- Viscous Fiber
- Where
- Canada
- Volunteers
- 1,394 people, healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Diabetes, Diabetes Mellitus, Type 1
Special Survey for Type 1 or Type 2 Diabetic Patients
This study is conducted in Japan. The aim of this study is to evaluate the incidence of severe hypoglycaemia episodes under normal clinical practice for patients with type 1 or type 2 diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01487408
- Testing
- insulin aspart
- Where
- Japan
- Volunteers
- 1,463 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Tandem Freedom - Feasibility Trial 2
This feasibility study is a prospective, single arm study evaluating the Tandem Freedom system in adults with type 1 diabetes. Existing Control-IQ technology users will use Control-IQ technology at home for a one week run-in…
- Trial name
- NCT06834568
- Testing
- t:slim X2 insulin pump with Tandem Freedom Algorithm
- Where
- New Zealand
- Volunteers
- 10 people
- Sponsor
- Tandem Diabetes Care, Inc.
Type 1 Diabetes Mellitus
Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus
Primary Objective: To assess the safety and tolerability of two dose levels of a new insulin glargine formulation in a once-daily multiple dosing regimen Secondary Objective: To compare the pharmacokinetic and pharmacodynamic…
- Trial name
- NCT01349855
- Testing
- Insulin glargine HOE901
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Sanofi
Type 1 Diabetes Mellitus With Diabetic Nephropathy
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through…
- Trial name
- ASPIRE-1 (NCT06072326)
- Testing
- Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin
- Where
- 5 sites in Denmark, Finland
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Weight Loss
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type…
- Trial name
- NCT07868835
- Testing
- VK2735
- Volunteers
- 560 people
- Sponsor
- Viking Therapeutics, Inc.
Microalbuminuria, Diabetic Nephropathy
Chicken-Diet vs. Enalapril to Reduce Albuminuria
Diabetic nephropathy (DN) is a chronic diabetic complication and affects up to 40% of patients. The first line treatment for DN is angiotensin blockers drugs that are used to reduce the protein concentration in urine.Previous…
- Trial name
- NCT00484068
- Testing
- enalapril, chicken diet
- Where
- Brazil
- Volunteers
- 28 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
Type1 Diabetes Mellitus
A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus
Primary Objective: To demonstrate bioequivalence between insulin glulisine given as 300 Units/mL test formulation and insulin glulisine 100 Units/mL reference formulation after a single subcutaneous (SC) dose.
- Trial name
- NCT02910518
- Testing
- Insulin glulisine (U300), Insulin glulisine, Insulin aspart
- Where
- Germany
- Volunteers
- 44 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Evidence for Health Improvement in People With Diabetes Using One Touch & Partner Solutions
ECLIPSE will evaluate the clinical and economic value of OneTouch Solutions in a real world study design. OneTouch Solutions describes a selection of devices and health and wellness solutions that people with diabetes (PWDs) can…
- Trial name
- ECLIPSE (NCT05354297)
- Testing
- Cecelia Health plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Fitbit plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app, Noom plus OneTouch Verio Reflect® BGM and OneTouch Reveal® mobile app
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- LifeScan
Type 1 Diabetes, Type 2 Diabetes
Arginase Inhibition in Type 1 and Type 2 Diabetes Mellitus
To evaluate the efficacy of arginase inhibition on endothelial function in patients with type 1 diabetes and type 2 diabetes.
- Trial name
- NCT05806502
- Testing
- Nω-hydroxy-nor-arginine
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Type 1
Diabetes Autoimmunity Withdrawn In New Onset and In Established Patients
The study is a prospective, randomized, 52-week double-blind, placebo-controlled, multicenter trial in subjects with Type 1 diabetes (T1D) followed by a 2-year safety follow-up.
- Trial name
- SUNRISE (NCT03895437)
- Testing
- TOL-3021
- Where
- 23 sites in United States
- Volunteers
- 78 people
- Sponsor
- Tolerion, Inc.
Hypoglycemia, Inflammatory Response
Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses
People with Type 1 diabetes (T1DM), type 2 diabetes (T2DM) and healthy volunteers will undergo a hypoglycaemic clamp to to investigate the effect of hypoglycaemia on cardiovascular and inflammatory responses.
- Conditions
- Hypoglycemia, Inflammatory Response, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- HCIR (NCT03976271)
- Testing
- hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp
- Where
- 2 sites in Denmark, Netherlands
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Diabetes Mellitus, Type 1
Hypoglycemia Thresholds in Type 1 Diabetes
The aim of this study is to compare the impact of hypoglycaemia treatment initiated at a blood glucose threshold of 65 mg/dL versus the internationally recommended threshold of 70 mg/dL on 2-hour post-treatment blood glucose…
- Trial name
- NCT07711275
- Testing
- threshold 70 mg/dL, threshold 65 mg/dL
- Where
- Turkey (Türkiye)
- Volunteers
- 33 people
- Sponsor
- Marmara University
Type 1 Diabetes, Type 2 Diabetes
Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port
The purpose of this study is to determine whether injecting Symlin and insulin through a multiple injection port is safe and effective.
- Trial name
- NCT00790699
- Testing
- I-PORT, standard injections
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Texas Diabetes & Endocrinology, P.A.
Diabetes Mellitus, Diabetes Mellitus, Type 1
PRECISION Study: Multi-center Study of Performance of a Novel Implanted CGM System Using a Next Generation Transmitter and Algorithm
The purpose of this multi-center, prospective clinical study is to evaluate the performance of a novel, implanted Senseonics continuous glucose monitoring system (Senseonics CGM System) compared to Yellow Springs Instrument (YSI)…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PRECISION (NCT03251079)
- Testing
- Continuous glucose monitoring system
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Senseonics, Inc.
Diabetes Mellitus, Type 1
Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy
An unblinded, randomized, cross-over design with each patient participating in two 40-hour outpatient admissions: (a) Experimental involving automated Control-to-Range (CTR) and (b) Control using Continuous Glucose Monitor (CGM)…
- Trial name
- NCT01714505
- Testing
- Diabetes Assistant (DiAs)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Virginia
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Obesity, Type 2 Diabetes Mellitus
XW004 To Evaluate the Safety, Tolerability, PK, and PD of Oral Ecnoglutide Tablet in Healthy Adults
XW004 is an acylated human glucagon-like peptide 1 (GLP-1) analogue and is being developed for type 2 diabetes mellitus (T2DM) and obesity management.
- Trial name
- NCT05184322
- Testing
- T2026, Oral ecnoglutide tablet
- Where
- Australia
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Sciwind Biosciences APAC CO Pty. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.